Competitive Advantages:
A novel molecule that can inhibit P. falciparum in malaria, Bypasses drug resistance, Limited toxicity towards human cells.
Described herein are compounds, formulations, and methods for blocking sporozoite invasion and subsequent liverstage parasite development of a protozoan parasite, such as Plasmodium falciparum.USF researchers have developed a novel modified hexapeptide called friomaramide. It inhibits the growth of P. falciparum to a similar degree as the antimalarial drug primaquine, with the added benefit of bypassing growing antimalarial resistance. It is also less toxic to human cells. Friomaramide may prove to be a huge benefit to the millions of people infected with malaria worldwide every year.
Brochure
